Impact of Dose-Dense Immunochemotherapy on Prognosis of Germinal Center and Non Germinal Center Origin of Diffuse Large B Cell Lymphoma

REFERENCES

• Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005; 106 (4): 1164–1174.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's Lymphoma. N Engl J Med 1993; 328 (14): 1002–1006.
   Google Scholar
• Illidge T, Tolan S. Current treatment approaches for diffuse large B-cell lymphoma. Leukemia Lymphoma 2008; 49 (4): 663–676.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus Rituximab compared with CHOP alone in eld-erly patients with diffuse large B cell lymphoma. N Engl J Med 2002; 346 (4): 235–242.
   Google Scholar
• Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermeet C al. Long-Term Results of the R-CHOP Study in the treatment of Elderly Patients With Diffuse Large B Cell Lymphoma: A Study by the Groupe d'Etude desLymphomes de l'Adulte. J Clin Oncol 2005; 23 (18): 4117–4126.
   Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23 (22): 5027–5033.
   Google Scholar
• Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn J et al. Rituximab-CHOP versus CHOP alone or with mainte-nance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24 (19): 3121–3127.
   Google Scholar
• Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Tmeny M, Imrie K et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diff use large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7 ( 5); 379-391.
   Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E et al.Six versus eight cycles of bi-weekly CHOP-14 with or with-out rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2006; 9 (2): 105-116.
   Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. New Engl J Med 1993; 329 (14): 987-994.
   Google Scholar
• Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins Pet al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109 (5): 1857–1861.
   Google Scholar
• Offit K, Lo Coco F, Louie DC, Parsa NZ, Leung D, Portlock C. Re-arrangement of the bc1-6 gene as a prognostic marker in diffuse large-cell lymphoma. New Engl J Med 1994; 331 (2): 74–80.
   PubMed Web of Science ®Google Scholar
• Akasaka T, Ueda C, Kurata M, Akasaka H, Yamabe H, Uchiyama T, Ohno H. Nonimmunoglobulin ( non-Ig)/BCL6 gene fusion in diffuse large B-cell lymphoma results in worse prognosis than Ig/BCL6. Blood 2000; 96 ( 8); 2907-2909.
   Google Scholar
• Barrans SL, O'Connor SJ, Evans PA, Davies FE, Owen RG, Haynes AP et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol 2002; 117 (2): 322-332.
   Google Scholar
• Pasqualucci L, Migliazza A, Basso K, Houldsworth J, Chaganti RS, Dalla-Favera R. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood 2003; 101 (8): 2914–2923.
   PubMed Web of Science ®Google Scholar
• Chaganti RS, Nanjangud G, Schmidt H, Teruya- Feldstein J. Recurring chromosomal abnormalities in non-Hodgkin's lymphoma: biologic and clinical significance. Sem Hematol 2000; 37 (4): 396–411.
   PubMed Web of Science ®Google Scholar
• Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JH et al. Clinical relevance of BCL2, BCL6, and MYC rearrange-ments in diffuse large B-cell lymphoma. Blood 1998; 92 (9): 3152-3162.
   Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene ex-pression profiling. Nature 2000; 403 (6769): 503–511.
   Google Scholar
• Colomo L, Lopez-Guillermo A, Perales M, Rives S, Martinez A, Bosch F et al. Clinical impact of the differentiation profile assessed by im-munophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101 (1): 78–84.
   Google Scholar
• Alacacioglu I, Ozcan MA, Ozkal S, Piskin O, Turgut N, Demirkan F et al. Prognostic significance of immunohistochemical classification of diffuse large B-cell lymphoma. Hematology 2009; 14 (2): 84–89.
   Google Scholar
• Uherova P, Ross CW, Schnitzer B, Singleton TP, Finn WG. The clinical significance of CD10 antigen expression in diffuse large B-cell lym-phoma. Am J Clin Pathol. 2001; 115 (4): 582–588.
   PubMed Web of Science ®Google Scholar
• Xu Y, McKenna RW, Molberg KH, Kroft SH. Clinicopathologic analysis of CD10 and CD10 diffuse large B-cell lymphoma: identification of a high-risk subset with coexpression of CD10 and bc1-2. Am J Clin Pathol. 2001; 116 (2): 183–190.
   PubMed Web of Science ®Google Scholar
• Chang CC, Cleveland RP, Perkins SL. CD10 expression and survival [letter]. Am J Clin Pathol. 2002; 117 (4): 660–661.
   PubMed Web of Science ®Google Scholar
• Hans C.P., 2004. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103: 275–282.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Broccoli A, Stefoni V, Musuraca G, Abruzzese E, De Renzo A et al. Immunophenotype and intermediate-high international prog-nostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. Cancer 2010; 116 (24): 5667–75.
   Google Scholar
• Ott G, Ziepert M, Klapper W, Horn H, Szczepanowski M, Bernd HW et al. Immunoblastic morphology but not the immunohistochemical GCB/non-GCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 2010; 116 (23): 4916-4925.
   Google Scholar
• Gerdes J, Dallenbach F, Lennert K, Lemke H, Stein H. Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67. Hematol Oncol 1984; 2 (4): 365–371.
   PubMedGoogle Scholar
• Rosemberg SA. Validity of the Ann Arbor staging classification for the NHLs. Cancer Treat Res 1977; 61 (6): 1023–1027.
   Google Scholar
• Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC et al. Report of a committee convened to discuss the evaluation and stag-ing of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7 (11): 1630–1636.
   Google Scholar
• Cheson BD, Homing SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response cri-teria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17 (4): 1244.
   Google Scholar
• SPSS Inc. SPSS for Windows, version 12.0 Chicago, IL: SPSS; 1998.
   Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assn 1958; 53: 457–481.
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50 (3): 163–70.
   PubMedGoogle Scholar
• Nyman Adde M, Karjalainen-Lindsberg ML, Taskinen M, Berglund M, Amini RM et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109 (11): 4930–4934.
   Google Scholar
• Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X et al. Addition of rituximab to standard chemotherapy improves the survival of both the Germinal Center B-Cell—Like and Non—Germinal Center B-Cell—Like subtypes of diffuse large B-Cell lymphoma. J Clin Oncol 2008; 26 (28): 4587–4594.
   Google Scholar
• Seki R, Ohshima K, Fujisaki T, Uike N, Kawano F, Gondo H. Prog-nostic impact of immunohistochemical biomarkers in diffuse large B-cell lym-phoma in the rituximab era. Cancer Sci 2009; 100 (10): 1842–1847.
   PubMed Web of Science ®Google Scholar
• Tarella C, Zanni M, Di Nicola M, Patti C, Calvi R, Pescarollo A et al. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia 2007; 21 (8): 1802–1811.
   Google Scholar
• Nyman H, Jantunen E, Juvonen E, Elonen E, Böhm J, Kosma VM. Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma. Bone Marrow Transplant 2008; 42 (2): 93–98.
   PubMed Web of Science ®Google Scholar